Faruqi & Faruqi Investigates Potential Securities Claims for Unicycive Investors

Investigation of Unicycive Therapeutics by Faruqi & Faruqi

Faruqi & Faruqi, LLP, a significant national securities law firm, is investigating potential legal claims on behalf of investors who have faced losses due to investments in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) from March 29, 2024, to June 27, 2025. The firm is urging affected investors to come forward and discuss their rights and options.

Background of Unicycive

Unicycive Therapeutics focuses on providing innovative therapies to treat diseases linked to kidney function. However, the company is currently entangled in legal scrutiny due to serious allegations of regulatory mishaps, particularly concerning their overdosing and compliance with FDA directives.

According to a recent press release issued on June 10, 2025, Unicycive admitted to deficiencies in Good Manufacturing Practice (GMP) during an inspection by the FDA of a third-party manufacturing vendor. This disclosure was a significant turning point, resulting in a dramatic drop in Unicycive's stock price, plummeting by 40.89% to close at $5.32 per share on that day.

Just a few weeks later, on June 30, 2025, Unicycive faced further challenges as it announced that the FDA had issued a Complete Response Letter regarding its New Drug Application (NDA) for a treatment tailored for hyperphosphatemia in patients receiving dialysis. The cited deficiencies at the third-party subcontractor, related to cGMP, exacerbated concerns among shareholders, leading to a subsequent stock crash of 29.85%, closing at $4.77 per share.

Legal Representation and Options

Faruqi & Faruqi, through their Securities Litigation Partner James (Josh) Wilson, has opened communication lines for affected investors. They are reminded that the deadline to apply as the lead plaintiff for a class action lawsuit is approaching on October 14, 2025. A lead plaintiff typically has the largest financial stake in the lawsuit and can influence the case's direction while representing the class of investors.

Investors seeking to discuss their options are urged to contact Faruqi & Faruqi directly at the contact numbers provided. The firm prides itself on a track record of recovering hundreds of millions of dollars for investors since its inception in 1995 and operates with offices in New York, Pennsylvania, California, and Georgia.

Potential Implications

The ongoing investigation into Unicycive raises critical questions regarding its management practices and adherence to federal regulations. Investors must stay informed on company updates and the development of the legal proceedings to understand potential repercussions on their investments.

In light of these developments, anyone who has information about Unicycive’s conduct, including whistleblowers, former employees, and shareholders, is encouraged to share their insights with the legal team at Faruqi & Faruqi.

For more details on the Unicycive Therapeutics class-action investigation and to learn about your rights as an investor, visit Faruqi & Faruqi's official page or directly reach out to their representatives. Continuous updates are made available through their social media channels on LinkedIn and X.

This investigation underscores the importance of investor vigilance and understanding the legal landscape surrounding securities law, especially when it comes to high-stakes therapeutic sectors like that of Unicycive's.